Navigation Links
The mouse that ROR'ed
Date:1/2/2014

Researchers at the University of California, San Diego School of Medicine report that an oncogene dubbed ROR1, found on chronic lymphocytic leukemia (CLL) B cells but not normal adult tissues, acts as an accelerant when combined with another oncogene, resulting in a faster-developing, more aggressive form of CLL in mice.

The findings, published in the Dec. 30, 2013 Online Early Edition of PNAS, suggest ROR1 could be an important therapeutic target for patients with CLL, the most common form of blood cancer. Prevalence of CLL in the United States is high: 1 in 20 people over the age of 40 could have apparently pre-cancerous CLL-like cells in their blood. These people may develop actual CLL at a rate of about 1 percent per year. More than 15,000 new cases of CLL are diagnosed each year in the United States. Roughly 4,400 patients with CLL die annually.

The work by principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues continues a series of discoveries about ROR1. Previously, for example, they found an association between ROR1 and the epithelial-mesenchymal transition the process that occurs during embryogenesis when cells migrate and then grow into new organs during early development. CLL cells exploit ROR1 to spread disease. Called metastasis, it is responsible for 90 percent of cancer-related deaths.

In the PNAS paper, Kipps and colleagues created transgenic mice that expressed human ROR1, then observed that these mice produced B cells (a kind of white blood cell) that were abnormal and resembled human CLL cells while non-transgenic littermates did not.

Next they crossed the ROR1 mice with another transgenic mouse-type that produces an oncogene called TCL1. Oncogenes are genes that can lead to cancer development if over-expressed or mutated. The progeny of these cross-bred mice possessed both oncogenes ROR1 and TCL1 and consequently displayed an even greater proclivity toward developing aggressive, fast-acting CLL.

When researchers treated the mice with an anti-ROR1 monoclonal antibody that reduces levels of ROR1, the CLL cells were impaired and more vulnerable to treatment and destruction. Based on these findings, Kipps said investigators at UC San Diego Moores Cancer Center are planning clinical trials in 2014 using a humanized monoclonal antibody that has the same type of activity against human leukemia or cancer cells that express ROR1.


'/>"/>

Contact: Scott LaFee
slafee@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related biology news :

1. H. pylori vaccine shows promise in mouse studies
2. New book on mouse models of cancer from Cold Spring Harbor Laboratory Press
3. Mouse studies reveal promising vitamin D-based treatment for MS
4. Elevated levels of copper in amyloid plaques associated with neurodegeneration in mouse models of AD
5. New agent inhibits HCV replication in mouse models -- No resistance seen
6. Cat and mouse: A single gene matters
7. New mouse viruses could aid hepatitis research
8. Omega-3s from fish vs. fish oil pills better at maintaining blood pressure in mouse model
9. UT Southwestern scientists make mouse model of human cancer, demonstrate cure
10. Researchers generate a mutant mouse model useful in the treatment of neuromuscular diseases
11. Transplanted neural stem cells slows als onset and progression in mouse models
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/6/2017)... , May 5, 2017 RAM ... announced a new breakthrough in biometric authentication based ... quantum mechanical properties to perform biometric authentication. These new ... semiconductor material created by Ram Group and its ... entertainment, transportation, supply chains and security. Ram Group ...
(Date:4/17/2017)... MELBOURNE, Florida , April 17, 2017 ... security technology company, announces the filing of its 2016 Annual Report ... Securities and Exchange Commission. ... Report on Form 10-K is available in the Investor Relations section ... well as on the SEC,s website at http://www.sec.gov . ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... Angeles, CA (PRWEB) , ... ... ... Inc., a development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, ... uses of targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
(Date:10/6/2017)... ... October 06, 2017 , ... The ... and technology sector at their fourth annual Conference where founders, investors, innovative practitioners ... and the ELEVATE pitch competition showcasing early stage digital health and med tech ...
Breaking Biology Technology: